Response to litigation

Oxford Nanopore Technologies, the UK-based company that sells the only nanopore sequencing device, the MinION portable DNA sequencer and is developing the high throughput/ high sample number PromethION device, responds to the patent lawsuit filed by Illumina, Inc. 


Dr Gordon Sanghera, CEO of Oxford Nanopore said "It is gratifying to have the commercial relevance of Oxford Nanopore products so publicly acknowledged by the market monopolist for NGS."

We do not anticipate any disruption to our ongoing commercial progress as a result of Illumina's action, which we believe is without merit.

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.